Poster: MPN-145 Retrospective Analysis of Anemia Benefit of Pacritinib From the PERSIST-2 Trial

Stephen Oh,Ruben Mesa,Claire Harrison,Prithviraj Bose,Aaron Gerds,Vikas Gupta, Ashwin Swami,Shanthakumar Tyavanagimatt,Sarah Buckley,Karisse Roman-Torres,Srdan Verstovsek

Clinical Lymphoma Myeloma and Leukemia（2022）

引用 0|浏览4

暂无评分

摘要

Improvement in hemoglobin levels and transfusion requirements was greater on PAC than BAT, in PERSIST-2. This anemia benefit could be due to PAC's ability to inhibit the iron regulator ACVR1, which has been linked to hepcidin reduction and anemia benefit. These data suggest an important role for PAC in anemic patients with myelofibrosis. This study was supported by CTI BioPharma.

查看译文

关键词

MPN,myelofibrosis,anemia,transfusion independence,ACVR1,pacritinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要